OPTIMAL VALUES OF TESTOSTERONE IN THE COURSE OF THE THERAPY OF ADVANCED PROSTATIC CARCINOMA Article published in Urologia Polska 1989/42/2.
authors
-
Jan Szymanowski, Ewa Ko¼mińska, Stefan Zgliczyński
- Z Oddzia³u Urologii Szpitala Bielańskiego w Warszawie
Ordynator: dr n. med. J. Szymanowski Z Kliniki Endokrynologii CMKP w Warszawie Kierownik: prof. dr hab. med. S. Zgliczyński
summary
- The aim of the work is to evaluate the influence of total testosterone (T) concentration in the blood serum on the stabilization of advanced prostatic adenoma. The stabilization mean the regression of complaints, lack of local carcinoma progression and preservation of normal activity of phosphates in the blood serum. Concentration T was determined in the blood serum of 45 patients with advanced prostatic carcinoma, among 14 (31.1°/o) with metastasis. The patients were administered phosthrolin and parlodel (orally). The observation lasted 5 years (on the average). Concentration T in the blood serum was 1?4 ng/ml in 22 (48.9%) patients, more than 4 ng/ml in 12 patients (26.7%), less than 1 ng/ml ? in 11 (24.4%) patients. The stabilization was observed in 39 (86.7%) patients whereas worsening in in 6 (13.3%), among them in 2 (4.4% of the total number) in whom the concentration was less than 1 ng/ml.
- It seems that the stabilization of prostatic carcinoma may be connected with the preservation of T concenrations in the blood serum typical for the age of patients.
references
- 1. Fukutani K., Isurugi K., Ishida H., Yokoyama M.: Effects of estrogens on the testosterone levels of peripheral and spermatic vein blood in patients with prostatic cancer. J. Urol., 1979, 122, 5, 624. ? 2. Hickey D., Todd B., Soloway M. 5.: Pre-treatment testosterone levels: significance in androgen deprivation therapy. J. Urol., 1986, 136, 5, 1038. ? 3. Labrie F.: New hormonal therapy for prostatic cancer: a combined treatment with an LHRH agonist and antiandrogen. J. Clin. Med., 1982, 5, 267. ? 4. Robinson M.R.G., Thomas B.S.: Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma. Brit. Med. J., 1971, 4, 391. ? 5. Schulze H., Isaacs J., Senge T.: Inability of complete androgen blockade to increase survival of patients with advanced prostatic cancer as compared to standard hormonal therapy. J. Urol., 1987, 137, 5, 909. ? 6. Shearer R. J., Hendry W. F? Sommerville I. F., Fergusson J. D.: Plasma testosterone: an accurate monitor of hormone treatment in prostatic cancer. Brit. J. Urol., 1973, 45, 668. ? 7. Szymanowski J., Baranowska B., Niewiadomska A., Wysocki M., Kobuszewska-Faryna M., Zgliczyński S.: L'interdependence entre les troubles hormonaux, le stade d'evolution et le degre de malignite du cancer de la glande prostatique (I). J. d'Urol., 1983, 89,
- 8, 597. ? 8. Szymanowski J., Baranowska B., Rozbicka G, Jeske W., Zgliczyński S.:
- L'interdxpendence entre les troubles hormonaux, le stade d evolution et le degre
- de malignite du cancer de la glande prostatique (II). J. d'Urol., 1983, 89, 9, 663. ?
- 9. Trachtenberg J.: Optimal testosterone concentration for the treatment of pros
- tatic cancer. J. Urol.. 1985, 133, 5, 888.
|